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Background: Gestational disorders such as intrauterine growth restriction (IUGR) and pre-eclampsia (PE) are main
causes of poor perinatal outcomes worldwide. Both diseases are related with impaired materno-fetal nutrient transfer,
but the crucial transport mechanisms underlying IUGR and PE are not fully elucidated. In this study, we aimed to
identify membrane transporters highly associated with transplacental nutrient deficiencies in IUGR/PE.
Results: In silico analyses on the identification of differentially expressed nutrient transporters were conducted
using seven eligible microarray datasets (from Gene Expression Omnibus), encompassing control and IUGR/PE
placental samples. Thereby 46 out of 434 genes were identified as potentially interesting targets. They are involved in
the fetal provision with amino acids, carbohydrates, lipids, vitamins and microelements. Targets of interest were
clustered into a substrate-specific interaction network by using Search Tool for the Retrieval of Interacting Genes.
The subsequent wet-lab validation was performed using quantitative RT-PCR on placentas from clinically well-
characterized IUGR/PE patients (IUGR, n = 8; PE, n = 5; PE+IUGR, n = 10) and controls (term, n = 13; preterm,
n = 7), followed by 2D-hierarchical heatmap generation. Statistical evaluation using Kruskal-Wallis tests was then
applied to detect significantly different expression patterns, while scatter plot analysis indicated which
transporters were predominantly influenced by IUGR or PE, or equally affected by both diseases. Identified by
both methods, three overlapping targets, SLC7A7, SLC38A5 (amino acid transporters), and ABCA1 (cholesterol
transporter), were further investigated at the protein level by western blotting. Protein analyses in total placental
tissue lysates and membrane fractions isolated from disease and control placentas indicated an altered functional
activity of those three nutrient transporters in IUGR/PE.
Conclusions: Combining bioinformatic analysis, molecular biological experiments and mathematical diagramming, this
study has demonstrated systematic alterations of nutrient transporter expressions in IUGR/PE. Among 46 initially
targeted transporters, three significantly regulated genes were further investigated based on the severity and the
disease specificity for IUGR and PE. Confirmed by mRNA and protein expression, the amino acid transporters
SLC7A7 and SLC38A5 showed marked differences between controls and IUGR/PE and were regulated by both
diseases. In contrast, ABCA1 may play an exclusive role in the development of PE.
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Worldwide, more than one third of child deaths can be
attributed to maternal and fetal undernutrition [1].
Along the course of gestation, the fetus receives organic
and inorganic nutrients from the mother, such as
amino acids, carbohydrates, lipids, vitamins and min-
erals, for adequate development and growth. To avoid
direct materno-fetal blood contact, the placenta has
distinctive anatomical barriers for regulating the sub-
strate exchange [2, 3]. Various molecules originating
from maternal blood enter the fetal circulation after
crossing successively the apical microvillous plasma
membrane (MVM), the cytoplasm, and the basal
plasma membrane (BM) of the trophoblast layer [3, 4].
On the other side, the fetus eliminates waste products
via efflux processes at the BM into the maternal veins.
This highlights the crucial role of substrate specific
membrane transporter proteins at these different loca-
tions. Indeed, for several membrane transporter pro-
teins (e.g. Ca2+ -ATPase, ferroportin, system A amino
acid transporters) an asymmetric distribution between
MVM and BM has been reported. Although this asym-
metry is a prerequisite for net transport across the pla-
centa via transporter proteins, the mechanisms of
protein trafficking that result in distribution to either
MVM or BM in the polarized syncytiotrophoblast are
largely unknown. It is evident, however, that any reduc-
tion of the quantity, density, and activity of membrane
transporters at the placental microvilli could impact the
rates of the nutrient supply, which may subsequently
compromise the fetal development. It is well recognized
that gestational diseases such as intrauterine growth re-
striction (IUGR) and pre-eclampsia (PE), which compli-
cate a significant proportion of pregnancies leading to
poor perinatal outcome, are closely related to impaired
placental nutrient transfer [5, 6].
Transfer of amino acids across the placenta is medi-
ated by substrate selective amino acid transport sys-
tems. So far, more than 15 different systems have been
identified in the human placenta, which include Na
+-dependent systems A, N, ASC, β, XAG−, XC−, GLY
and Na+-independent systems L, y+, y+L, T, bo,+ [5, 7,
8]. Reduced activity of amino acid transporters e.g. sys-
tem A in IUGR and PE has been reported [9–11],
which might be due to reduced sodium-potassium
ATPase (Na+/K+ATPase) activity [12] and a competitive
inhibition by physiologically elevated maternal plasma
homocysteine [13, 14]. The transplacental transport of
glucose mainly occurs along a concentration gradient
facilitated by the glucose transporter (GLUT) family,
while lipids are mostly packed into circulating protein
particles by virtue of active membrane transporters
[15]. Current knowledge in this field revealed an in-
creased concentration gradient from maternal to fetalsides in IUGR and PE to achieve higher glucose and
lipid transfer [16, 17]. These significant elevations have
also been considered as a risk factor for those gesta-
tional disorders [18, 19], which may be explained by an
altered expression of membrane transporter [20, 21].
The fetal provision with vitamins and dietary ele-
ments is required, since they are essential to regulate
the fetal metabolism as well as extra- and intra-cellular
osmolality. Global studies under the auspices of the
World Health Organization in 2008 proposed that defi-
ciencies in micronutrients such as thiamine (Vitamin
B1), riboflavin (Vitamin B2), folate (Vitamin B9), co-
balamin (Vitamin B12), and ascorbic acid (Vitamin C),
are highly prevalent and occur concurrently among
pregnant women [1]. It has been reported that the ele-
vated serum homocysteine levels in IUGR and PE were
accompanied by decreasing serum levels of the afore-
mentioned class B vitamins. The dietary treatment of
pregnant women with diverse vitamin B supplements
improved fetal weight [22–26]. However, data regarding
the transplacental transport of vitamin B are scarce. In
this context SLC19 family members were found to
transport folate (SLC19A1) and thiamine (SLC19A2
and SLC19A3) [27]. Interestingly, in IUGR placentas,
an increase in mRNA level of SLC19A1 and SLC19A2
has been reported [28], which was interpreted as a
compensatory effect. Besides, deficiencies in serum cal-
cium, magnesium and zinc might greatly contribute to
the pathogenesis of PE, since it was suggested that the
dietary supplementation of these elements can reduce
the severity of PE [29–31]. Although calcium is pro-
bably the most studied element among all ions, pu-
blications investigating the role of transporters or
exchangers in placental calcium homeostasis are negli-
gible (< 20). It was found that the expression of Ca2+-se-
lective receptor channels and Na+/Ca2+ exchangers were
significantly increased in hypertensive placentae compared
to normotensive tissues [32].
The studies mentioned above and numerous others
have suggested that an altered transplacental nutrient
transport might elicit IUGR/PE [5, 6, 33]. However,
the detailed underlying mechanisms involving mem-
brane transporters are still not fully elucidated. There-
fore, we conducted the current study to gain a
comprehensive knowledge on the importance of pla-
cental transporter proteins majorly involved in the
fetal provision with amino acids, carbohydrates and
derivatives, lipids, vitamins, and microelements. We
hypothesized that the expression of placental mem-
brane transporters was modified by IUGR/PE. To
identify the key nutrient transporters in placenta, we
have used a multifaceted approach including bioinfor-
matic analysis, molecular biology, and mathematical
diagramming (Fig. 1).
Fig. 1 Strategy to target nutrient transporters in intrauterine growth
restriction and pre-eclampsia using multiple approaches. The funnel
like structure of the different analytical approaches represents the
decreasing number of targets which overlap in every step of the
analyses. Originating from 434 genes in meta-analysis of microarray
data (1), 46 differentially expressed candidate genes were selected and
clustered by STRING network (2). Gene expression screening of an in
house placental tissue collection in the laboratory (3) was analysed by
statistical evaluation and mathematical diagramming (4). The resulting
3 overlapping transporters were finally subjected to the biochemical
analyses of protein translation and membrane localization
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Identification of target transporters by microarray
processing
Publicly available data was obtained at http://www.
ncbi.nlm.nih.gov/geo through the accession numbers
GSE 25861, 24129, 12216, 25906, 14722, 35574, 24818.
Robust multi-array averaging (RMA) and quantile
normalization were used to quantify gene expression.
Significant differences were identified applying a Bayes-
ian approach using the limma package (R 3.1, Bio-
conductor 2.7). We analysed gene expression data of
solute carriers (SLCs), ATP-binding cassette transporters
(ABCs) and transient receptor potential channels
(TRPs). Any SLC, ABC and TRP family member, which
i) was represented in more than 3 studies, ii) was listed
in top 12 up- or down-regulated genes, and iii) has an
annotated a biological significance in placenta, was
added to the candidate list.
Visualization of biomolecular interaction network
To better understand the network of the identified nutri-
ent transporters from microarray data, we applied the
identified targets of interest to Search Tool for the Re-
trieval of Interacting Genes (STRING) 9.1 at http://
string-db.org with a focus on the direct (physical) and
indirect (functional) targets’ connections. In the STRING
tool, we restricted the prediction to human placenta
with medium protein-protein interactions (associated
with a confidence score larger than 0.4), and clustered
by the Markov cluster algorithm (MCL).Placental sample collection
The study was approved by the local ethic institutional
review board of the Canton of Bern with an informed
consent obtained from each participant prior to the cae-
sarean section. Pregnant women were under obstetrical
care at the Department of Obstetrics and Gynecology,
University Hospital (Bern, Switzerland). They were
assigned to five groups: term controls, preterm, IUGR,
PE, and PE combined with IUGR (PE + IUGR). Term
controls consisted of the pregnancies without patholo-
gies and terminated at term (≥ 37 gestational weeks) by
elective primary caesarean section upon patients’ request
or due to breech presentation. The preterm group was
defined as the babies born prior to 37 weeks of preg-
nancy, but without further abnormal maternal or fetal
symptoms. According to the definition from the Inter-
national Society for the Study of Hypertension in Preg-
nancy, patients with the dramatic increase of systolic/
diastolic blood pressure (> 140/90 mmHg) and urinary
protein content in 24 h (> 0.30 g) were classified in PE
related groups. When the fetal birth weight was below
the 10th percentile for babies of the same gestational age,
the baby was also referred to as small for gestational age
due to the IUGR effects. As it is a severe complication
when PE occurs concomitantly with IUGR, we also in-
cluded and characterized patients suffering from PE
combined with IUGR (PE + IUGR).
Placental tissue collection was performed and fully val-
idated as previously described [21, 34]. Immediately after
caesarean section, chorionic tissue was dissected from a
standardized central location, and snap-frozen in liquid
nitrogen after a thorough wash with Dulbecco’s phos-
phate buffered saline (Gibco). The collected tissue speci-
mens were stored at -80 °C until further analysis.
Quantitative RT-PCR
Total RNA was isolated from placental tissue with a
modified protocol, using a Trizol reagent kit (Invitrogen)
[34]. Approx. 50 mg frozen placental tissues were ho-
mogenized in 1 ml cold Trizol on ice with a Polytron
homogenizer (Kinematica AG), followed by phenol/
chloroform extraction and precipitation by isopropanol,
and final washing with 75% ethanol. After re-suspension
in RNase free water, the extracted RNA was evaluated
qualitatively (assessment of RNA integrity) by using Agi-
lent 2100 Bioanalyzer (Agilent Technologies) and quan-
titatively (determination of RNA concentration) with
NanoDrop 1000 (Thermo Scientific). All samples used
in this study fulfilled the fixed selection criteria which
were: RNA integration number (RIN) > 6, spectrophoto-
metric measurements at 260/280 > 2.0 and 260/230 > 1.8,
and the yield of RNA > 5 ng/μl.
Two microgram RNA was reverse transcribed into
cDNA using GoScript™ Reverse Transcriptase System
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performed in 10 μl volume with 1 μl cDNA template,
0.3 μM specific primers (listed in Additional file 1) and
GoTaqW qPCR Master Mix (Promega) on the ViiA™ 7
Real-Time PCR System (Applied Biosystems). Based on
the results of the transporter mRNA expression, the
heatmap was generated using centred correlation (Clus-
ter 3.0) and average linkage clustering analysis for simi-
larity measurement and clustering (TreeView at http://
diyhpl.us/~bryan/irc/protocol-online/protocolcache/
EisenSoftware.htm). The consecutive statistical analysis
and mathematical diagramming served for the identifica-
tion of significant and disease-specific targets,
respectively.
Total protein and membrane fraction extraction
To extract total protein from placenta, tissue samples
were homogenized in ice-cold hypotonic buffer (10 mM
Tris-HCl, 10 mM NaCl, 1.5 mM MgCl2 and 0.1% Triton
X-100, pH 7.4) supplemented with protease inhibitor
cocktail (Sigma), and centrifuged at 1000 × g for 10 min
at 4 °C. The supernatants were collected in fresh tubes
and stored at -80 °C.
Membrane fractions from placenta tissues were ex-
tracted using membrane, nuclear and cytoplasmic pro-
tein extraction kit according to the manufacturer’s
protocol (Bio Basic Inc.). The whole extraction proced-
ure was carried out on ice in the presence of protease
inhibitor, phosphatase inhibitor, dithiothreitol and phe-
nylmethylsulfonyl fluoride (PMSF). The “identity” of the
extracted cellular membrane fractions was validated by
detecting the corresponding expression of the plasma
membrane marker Novus Biologicals, the nuclear marker
histone H3 (Novus Biologicals) and the cytoskeleton
marker β-actin (Sigma).
The protein content of total lysates and membrane
fractions was quantified by bicinchoninic acid assay
(Pierce), using bovine serum albumin as standard.
Western blotting
90 μg of the total tissue lysate or 30 μg of membrane
fraction was mixed with Laemmli sample buffer and sep-
arated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (Bio-Rad) using 10% acrylamide gels.
The immobilized bands were then semi-dry transferred
to nitrocellulose membranes (GE Healthcare). Blots were
blocked with 5% non-fat milk in Tris Buffered Saline
with 0.1% Tween-20. The following antibodies were
used: rabbit anti-ABCA1 (Novus Biologicals), rabbit
anti-SLC7A7 (Novus Biologicals), and rabbit anti-
SLC38A5 (Aviva Systems Biology), as well as mouse
anti-β-actin or mouse anti-Na+/K+ ATPase as internal
controls. Primary antibodies were first incubated over-
night at 4 °C followed by 4 times washing with Tris-buffered saline supplemented with 0.1% Tween 20
(TBST), and then incubation with DyLight 680 or 800
fluorescence conjugated secondary antibodies (Thermo
Scientific). The immunoreactive bands were visualized
with the OdysseyW Sa Infrared Imaging System (LI-
COR) to obtain relative densitometry values.Statistical analysis and mathematical diagramming
The comparative threshold cycle (Ct) method was ap-
plied to analyze relative gene expression by fold change
= 2−Δ(ΔCt), where ΔCt = Cttarget gene - Ctreference gene and
Δ(ΔCt) = Δ(ΔCttest - ΔCtcontrol) [35].
Data were statistically evaluated using GraphPad Prism
6 Software. Kruskal-Wallis analysis followed by a Dunn’s
multiple comparison test, were used to analyse statistical
differences of the clinical records, the mRNA and pro-
tein expression data between the term controls and pre-
term, IUGR, PE and PE + IUGR groups. A p value of less
than 0.05 was considered statistically significant.
In addition, scatter plotting was applied to estimate
the influence of gestational diseases on transporter ex-
pression. Each point depicts a nutrient transporter,
whose x-axis and y-axis represents the average log 2-fold
changes (FC) in the IUGR group and PE group, respect-
ively. To avoid possible bias (individual variation, experi-
mental error, etc.), we selected only those targets, whose
expression has been modulated with an absolute FC >
1.14 (i.e. > 114% or < 86%) over the expression in the
term controls [36]. Subsequently, the ratio of y to x was
considered as a rank variable. When the ratio is close to
0, it means that the predominant effect on transporter
mRNA expression is caused by PE. Conversely, when it
approaches infinity, the altered transporter is primarily
influenced by IUGR. An intermediate state (i.e. a ratio
equal to 1 or -1), indicates an equal (1) or an equal but
reversed (-1) impact on the transporter expression level
by IUGR and PE.Results
Microarray processing
Six placental gene expression studies focusing on IUGR/
PE plus one project investigating umbilical cords associ-
ated with low birth weight, were included in this meta-
analysis (Table 1). These studies represented in total 258
samples, including 129 controls (term and preterm sam-
ples), 67 IUGR-related specimens and 62 PE placentas.
Based on the selection criteria for potential transporter
candidates described in the section Methods, 46 of the
434 genes were chosen for consecutive analysis. These
genes encode amino acids, carbohydrates and deriva-
tives, lipids, vitamins, microelements, and other trans-
port channels (Table 2). Among the selected targets, 32
genes exhibited increased expression levels in
Table 1 Microarray databank information
Citation Data
sources
Publication
date
Platform Sample origin Sample size Probes
Control IUGR PE
Dunk et al. [52] GSE25861 2012-04-01 Affymetrix Isolated PIMEC 3 (p) 6a 54,675
Nishizawa et al. [53] GSE24129 2010-09-15 Affymetrix Placenta 8 (m) 8 8 32,321
Sitras et al. [54] GSE12216 2008-08-01 Applied Biosystems Placenta 8 (m) 8a 32,878
Tsai et al. [55] GSE25906 2010-12-10 BeadArray Placenta 37 (m) 23 48,701
Winn et al. [56] GSE14722 2009-02-06 Affymetrix Placenta 11 (p) 12 42,928
Guo et al. [57] GSE35574 2012-02-07 Illumina Placenta 40 (m) 27 19 48,701
GSE24818 2011-10-21 Agilent Umbilical cord 22 18 37,903
Data used for meta-analysis was obtained by analysing the Gene Expression Omnibus (GEO) at http://www.ncbi.nlm.nih.gov/geo
(p) preterm controls (m) mixture of preterm and term controls
Abbreviation: PIMEC Fetoplacental microvascular endothelial cell
aIUGR is defined as birth weight < 5th percentile
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genes showed the opposite trend.Integration of interaction between selected candidates
As one of the largest database for protein interactions,
STRING aggregates the most available information (e.g.
neighbourhood, gene fusion, co-occurrence, co-expression,
experiments, databases, text mining and homology) de-
rived from genomic context, high throughput experiments,
co-expression and previous knowledge. Using the medium
confidence score and clustered by MCL, 46 signature nu-
trient transporters were mapped into an interaction net-
work (Fig. 2). The nodes visualize the proteins with known
structure, and the solid lines represent the predicted func-
tional associations with dashed inter-cluster edges. On
grouping the network, it summarized the predicted associ-
ations for a particular group of proteins, for instance,
amino acids associated transporters (blue cluster), vitamins
associated transporters (red cluster), microelements and
ions associated transporters (yellow cluster). The STRING
view depicted that the selected targets were clearly clus-
tered and strongly interconnected based on their substrate
specificity, which reflected a high degree of functional as-
sociation and a potential interplay among the nutrient
transporters.Identification of altered transporter gene expression in
IUGR/PE
Characterization of patients
To validate the gene expression on a well characterized,
clinically annotated tissue set, we have performed quanti-
tative RT-PCR measurements on a number of accredited
representative samples. Table 3 shows the demographic
and clinical characteristics of the studied population.
There were no major differences in the age, BMI, gravidity
and parity numbers between the patients. The gestational
age clearly isolated the term pregnancies from the rest,which was directly related with the placental weight and
the birth weight.
In addition, as a PE related biomarker, placental leptin
mRNA levels have been measured. A significantly in-
creased expression of leptin has been shown in PE and
PE + IUGR compared to both term and preterm control
placentae, but not in isolated IUGR (data not shown).
Selection of reference genes
Prior to evaluating the nutrient transporter regulation in
IUGR/PE, we first screened the mRNA abundance of
commonly used reference genes: β2-microglobulin, mito-
chondrial ribosomal protein L19, ubiquitin (UBQ), and
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, zeta polypeptide (YWHAZ). We found
no differences between controls and the herein tested ges-
tational diseases (data not shown). In accordance with our
previous work [34], the mean value of UBQ and YWHAZ
was used for quantitative RT-PCR normalization of target
nutrient transporters.
Gene expression analysis
We evaluated the expression of the selected 46 targets in
43 well-characterized placenta samples using unsuper-
vised hierarchical clustering. The heatmap shown in
Fig. 3 illustrates an overview of the expression profiles of
these transcripts based on the quantitative RT-PCR re-
sults. The generated expression profile data confirmed
that the 43 well-characterized placenta samples used in
this study highly reproduced the results obtained from
microarray data of 258 samples all over the world.
Based on Kruskal-Wallis test, eight candidate trans-
porters were identified showing significant changes on
mRNA expression among gestational disorders: the
amino acid transporters SLC7A7 (Fig. 4a), SLC38A2
(Fig. 4b), SLC38A5 (Fig. 4c), the glucose transporter
SLC2A1 (Fig. 4d), the cholesterol transporter ABCA1
(Fig. 4e), the vitamin B transporters SLC19A3 (Fig. 4f )
Table 2 Selected nutrient transporters according to their regulational signature and physiological significance
Substrate class Predominant (predicted)
substrate
Gene
name
Accession
number
Protein
name
Log (FC) Representative
references
Amino acids System L, y+L, xc-and asc [58, 59] SLC3A2 NM002394 4F2hc − 0.42~ 0.28 [60–63]
Cationic L- amino acids SLC7A1 NM003045 CAT1 − 0.52~ 0.89 [64–67]
Large neutral L-amino acids SLC7A5 NM003486 LAT1 −0.38~ 0.46 [62, 63, 66, 68–71]
Cationic amino acids, large
neutral L-amino acids
SLC7A6 NM003983 y+LAT2 −0.23~ 0.39 [69, 72]
SLC7A7 NM001126105 y+LAT1 − 0.44~ 0.89 [72]
Neutral L – amino acids SLC7A8 NM012244 LAT2 −0.12~ 0.25 [73]
Cystine (anionic form),
L-glutamate
SLC7A11 NM014331 xCT −0.10~ 0.53 –
Gln, Ala, Asn, Cys, His, Ser SLC38A1 NM030674 SNAT1 −0.28~ 1.24 [68, 74, 75]
Ala, Asn, Cys, Gln, Gly,
His, Met, Pro, Ser
SLC38A2 NM018976 SNAT2 − 0.11~ 0.11 [50, 68, 75–78]
Gln, Asn, His, Ser SLC38A5 NM033518 SNAT5 0.01~ 0.21 [49]
Polyamines, amino acids [79] SLC12A8 NM024628 CCC9 −0.45~ 1.09 –
Vitamins Thiamine [27] SLC19A2 NM006996 THTR1 0.28~ 0.66 [80]
SLC19A3 NM025243 THTR2 −1.17~ − 0.12 [80, 81]
Folate SLC19A1 NM194255 RFC −0.10~ 0.84 [82–85]
SLC46A1 NM080669 PCFT − 0.15~ 0.05 [82, 86]
Biotin, pantothenic
acid [87]
SLC5A6 NM021095 SMVT 0.01~ 0.04 [88, 89]
Cobalamin [90] LMBRD1 NM018368 LMBRD1 −0.26~ 0.22 –
(Pyridoxine) [91] SLC22A15 NM018420 FLIPT1 −0.14~ 0.10 –
L-ascorbic acid [92, 93] SLC23A1 NM005847 SVCT1 0.01~ 0.10 [94, 95]
SLC23A2 NM005116 SVCT2 −0.38~ 0.43 [95–97]
SLC23A3 NM144712 SVCT3 − 0.21~ 0.33 –
Microelements and ions Zn2+ [98, 99] SLC30A1 NM021194 ZNT1 −0.02~ 0.34 [100–102]
SLC30A2 NM032513 ZNT2 − 0.06~ 0.17 [100, 101, 103]
SLC30A4 NM013309 ZNT4 −0.21~ 0.05 [100, 101]
SLC39A1 NM014437 ZIP1 − 0.13~ 0.04 [100]
SLC39A8 NM022154 ZIP8 0.00~ 0.95 [104]
Ca2+ TRPV6 NM018646 TRPV6 0.02~ 0.43 [32, 105–107]
e.g. Cl−,(COO)2
2− [108] SLC4A1 NM000342 AE1 −0.48~ 0.53 [109, 110]
e.g. SO4
2− [111] SLC26A2 NM000112 DTDST −0.78~ 0.74 [43, 112]
SLC26A6 NM134426 Pat-1 − 0.09~ 0.47 [112]
e.g. Na+, H+ [113, 114] SLC9A1 NM003047 NHE1 −0.34-0.00 [110, 115–117]
SLC9B2 NM178833 NHA2 − 0.35~ − 0.34 –
e.g. I− [111, 118] SLC5A5 NM000453 NIS −0.12~ 0.08 [119–122]
SLC26A4 NM000441 PDS 0.00~ 0.04 [121, 123, 124]
e.g. Fe2+, Zn2+ [125] SLC11A2 NM000617 DMT1 −0.07~ 0.67 [126–128]
Lipids Cholesterol, phospholipids
[129]
ABCA1 NM005502 ABCA1 −0.19~ 0.71 [21, 130, 132]
ABCG1 NM207629 ABCG1 − 0.20~ 0.33 [130, 131]
Drugs, toxins [133] ABCG2 NM004827 ABCG2 −0.70~ 0.48 [134–136]
e.g. flavonoids [137] SLC47A1 NM018242 MATE1 −0.03~ 0.33 [138, 139]
LCFA, VLCFA [140] SLC27A2 NM003645 FATP2 −0.58~ 1.37 [141, 142]
SLC27A4 NM005094 FATP4 − 0.04~ 0.05 [142–144]
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Table 2 Selected nutrient transporters according to their regulational signature and physiological significance (Continued)
Substrate class Predominant (predicted)
substrate
Gene
name
Accession
number
Protein
name
Log (FC) Representative
references
Carbohydrates (+ metabolic derivatives) Glucose [145] SLC2A1 NM006156 GLUT1 0.12~ 0.66 [20, 40, 146]
Lactate [147] SLC16A1 NM003051 MCT1 −0.36~ 1.35 [148–150]
SLC16A3 NM004207 MCT4 − 0.12~ 0.48 [148–151]
SLC16A4 NM004696 MCT5 − 0.50~ 0.47 [149]
Neurotransmitter Norepinephrine [152] SLC6A2 NM001043 NET −0.31~ 0.54 [153–155]
Forty six entries were ordered alphabetically by gene name; pivotal information of targets including a representative example of accession number, and protein
name, substrate (class), and Log (FC) value from meta-analysis is listed
Abbreviations: SLC solute carrier, LCFA long chain fatty acid, VLCFA very long chain fatty acid
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porter SLC26A2 (Fig. 4h). In order to directly compare
the trend of gene regulation in IUGR or PE with the
microarray analysis, we have presented the gene expres-
sion as the log (FC) to term controls. Almost all trends
of alteration of transporters by IUGR/PE were compar-
able to those derived from microarray data, except the
effects on ABCA1 and SLC38A2 by PE. The latter might
be due to different criteria on PE sample selection,
which result in greater variations between microarrays.
In addition, mathematical diagramming was applied to
assess whether IUGR or PE is the major modulator ofFig. 2 Functional interaction networks of proteins encoded by the potential
were clustered by Search Tool for the Retrieval of Interacting Genes (STRING).
customized settings, including medium confidence of 0.4, Markov cluster
fusion, co-occurrence, co-expression, experiments, databases, text mining
substrate-specific components, which are vitamin transporters, microelements
available 3D protein structural information is embedded in the node, andthe determined alteration in gene expression. In the
scatter plot shown in Fig. 5, each point represents the
average expression level of one nutrient transporter. The
log (FC)IUGR and log (FC)PE of independent transporters
obtained from quantitative RT-PCR analysis, were de-
fined as paired X-Y values. The absolute value on the X-
axis or Y-axis reflects the severity of the gene expression
changes by IUGR or PE, respectively. By ranking the ab-
solute X or Y value, the top 3 genes dominantly influ-
enced by IUGR were SLC23A1, SLC26A2, and SLC7A11
(yellow squares), while SLC16A4, ABCA1, and ABCG2
(blue squares) were regulated mainly by PE. On thecandidate targets. Forty six transporters selected from microarray analysis
The protein-protein interaction in human placenta was performed using
algorithm (MCL) and 8 criteria for linkage (neighbourhood, gene
and homology). The red, yellow and blue clusters highlight the
and ion transporters, and amino acid transporters, respectively. The
the dashed lines represent the inter-cluster edges
Table 3 Demographics and clinical characteristics of the studied population
Term Preterm IUGR PE + IUGR PE p-value
Age, y 33.2 34.0 35.3 32.0 28.7 0.41, ns
[24.5-41.6] [29.1-40.7] [20.9-38.2] [27.3-40.2] [23.4-33.3]
Body mass index (BMI), kg/m2 21.3 22.8 24.6 23.3 24.1 0.32, ns
[18.6-32.8] [21.5-28.9] [20.8-35.5] [19.8-26.0] [19.8-31.9]
Gravidity 2.5 2.5 2.0 2.0 1.2 0.09, ns
[2.0-5.0] [1.0-6.0] [1.0-3.0] [1.0-4.0] [1.0-2.0]
Parity 2.0 2.0 2.0 2.0 1.0 0.06, ns
[1.0-4.0] [1.0-3.0] [1.0-3.0] [1.0-3.0] [1.0-2.0]
Gestational age, weeks 38.8 33.8** 35.9* 29.7*** 33.7* < 0.001
[38.3-39.9] [26.1-34.6] [21.7-39.3] [25.3-36.3] [25.4-36.0]
Placental weight, g 547.0 393.5 324.0* 300.0** 365.1 0.003
[398.0-1035.0] [250.0-810.0] [126.0-487.0] [132.0-481.0] [203.0-632.0]
Birth weight, g 3340.0 2127.5* 1850.0** 1170.0*** 1973.5 * < 0.001
[2950.0-3695.0] [745.0-2510.0] [210.0-2695.0] [520.0-2125.0] [605.0-2830.0]
Systolic blood pressure, mmHg 109.5 116.5 126.0 170.0*** 164.4** < 0.001
[90.0-125.0] [100.0-146.0] [109.0-156.0] [150.0-200.0] [147.0-213.0]
Diastolic blood pressure, mmHg 64.0 73.5 75.0 100.0*** 98.7*** < 0.001
[50.0-83.0] [67.0-91.0] [63.0-94.0] [95.0-124.0] [93.0-104.0]
Proteinuria, g/24 h < 0.15 < 0.15 < 0.15 0.88 2.8
[0.32-2.54] [0.5-6.0]
Statistical analysis was performed using Kruskal-Wallis with Dunn’s multiple comparisons test. Data are presented as median with range in brackets; ns, *, **, ***
represent a p-value > 0.05, < 0.05, < 0.01, and < 0.001, respectively, of the comparison between the tested group and the term control. Details on patient selection
and exclusion criteria are as described in Results (section “Identification of the altered transporter gene expression in IUGR/PE”).
Abbreviations: Term, healthy pregnancies at term; Preterm, uncomplicated preterm labour; IUGR, intrauterine growth restriction; PE, pre-eclampsia; PE + IUGR, PE
combined with IUGR
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SLC7A8 (red squares), were equally affected by IUGR
and PE since they locate on the y = x or y = −x line.
Taking into account the statistical analysis and the
mathematical diagramming, the overlapping targets,
namely ABCA1, SLC7A7, SLC38A5, and SLC26A2, were
further subjected to protein quantification. However, due
to the lack of a specific, validated antibody, the evaluation
of SLC26A2 protein could not be further pursued.
Protein levels of the key membrane transporters
Using immunoblotting technique, we complemented the
quantitative RT-PCR data with corresponding protein
expression levels. As shown in Fig. 6, the total protein
content of ABCA1 was significantly decreased by PE. In
contrast, SLC7A7 transporter showed significant up-
regulation in placentae associated with PE, while down-
regulation in IUGR placentae was found. SLC38A5
expression in placenta tissue was only slightly elevated
in IUGR and PE. The loss of significance may due to the
limited sample size. Generally, the changes found on
protein level for the three transporters ABCA1, SLC7A7
and SLC38A5, corresponded well with the transcrip-
tional results.As the target transporters modulate the fluxes of sub-
strates through the plasma membrane to meet fetal re-
quirements, we also isolated plasma membrane protein
fractions from the placentae, and confirmed their high
purity by enrichment of the marker protein Na+/K+
ATPase (data not shown). The latter was further used to
normalize the transporter protein expression detected by
Western blotting.
We have previously reported that the protein expres-
sion of the lipid transporter ABCA1 in extracted plasma
membranes was significantly reduced only in PE placen-
tae [21]. These findings were confirmed in the present
study (data not shown). Interestingly, the opposite regu-
lations for SLC7A7 protein between IUGR and PE-
associated disease types that we detected in tissue lysates
(Fig.6) were generally also reflected in extracted plasma
membrane preparations (Fig. 7). Normalization to β-
actin and Na+/K+ ATPase revealed a trend to decreased
expression of SLC7A7 in IUGR tissues, and confirmed a
significantly increased expression in PE tissues (Fig. 7a).
SLC38A5 was not significantly altered in membrane pro-
teins obtained from diseased and healthy (control) pla-
centas (Fig. 7b). However, marked increases in IUGR
and PE compared with the preterm group were found.
Fig. 3 Nutrient transporter mRNA expression profiles of placenta tissues. Heatmap generated from quantitative RT-PCR data from an in-house
placental tissue collection, hierarchically clustering the gene expression values of 46 transporters in selected gestational conditions. The clinical
status of individual patients, e.g. term (n= 13), preterm (n= 7), intrauterine growth restriction (IUGR, n= 8), pre-eclampsia (PE, n = 5), PE combined with
IUGR (PE + IUGR, n= 10), is indicated on the top, and gene names are listed on the right. Up-regulated expressions are marked in red, down-regulations
are coloured in green; black reflects no difference in expression levels
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Fetal growth is largely dependent on the availability of
nutrients transported into the fetal circulation via the
placenta. The transport of macro- and micronutrients
across the placental barrier relies on the presence and
activity of substrate specific membrane transporters. The
altered expression of these transporters is thought to be
implicated in diverse mechanisms of the fetal develop-
ment. The current study focused on studying to what
extent and which specific transporters are impaired by
IUGR or PE. To this end, we screened the expression
profiles of nutrient transporters whose substrates are
amino acids, carbohydrates, lipids, vitamins and microel-
ements in diseased and control placentas by analysing 7
publicly available GEO microarray datasets. The selected
targets have been further validated on in-house well-
characterized placenta tissues. A systematic alteration in
mRNA expression of diverse transporters were identified
in IUGR/PE. Among the 46 nutrient transporters, 8 were
significantly regulated by those gestational disorders. In
particular, the amino acid transporters SLC7A7 andSLC38A5 were strongly influenced by both IUGR and
PE. The mRNA and protein expression of the choles-
terol transporter ABCA1, by contrast, was only regulated
under PE condition.
Microarray gene expression data provided a global
overview on the nutrient transporter expression. How-
ever, the weakness of these data was that they were de-
rived from studies using not exactly the same criteria for
the clinical recruitment of patients. In this study, we
have systematically reviewed our on-site collected sam-
ples in the following ways. First, the applied clinical and
diagnostic data for each individual did meet the strictly
defined clinical criteria for classification as IUGR or PE
(Table 3). Second, the higher gene expression of leptin
occurring only in the PE and PE + IUGR groups served
as a placenta-derived marker of PE [37, 38]. Third, we
have compared the regulated mRNA expressions that
were generated on our 43 in-house samples with results
from the cohort of character-matched 258 patients in
seven microarray projects. It showed that only 26% of
the targets exhibited inconsistent pathological effects
Fig. 4 Identification of transporters with a significantly aberrant
expression pattern in gestational diseases. The expression patterns of
nutrient transporters in placental tissues obtained from controls and
the gestational diseases described in Fig. 3 were screened by
quantitative RT–PCR. Based on Kruskal-Wallis test (p < 0.05), eight
candidate transporters showed significantly altered mRNA
abundance in patients, i.e. SLC7A7 (a), SLC38A2 (b), SLC38A5 (c),
SLC2A1 (d), ABCA1 (e), SLC19A3 (f), SLC22A15 (g) and SLC26A2 (h).
Log 2-fold change (FC) values of gene expressions are shown as scatter
plots with lines drawn at median ± range. Each symbol represents the
gene expression of one individual. In the same figure, the differential
expression trends of transporters in IUGR or PE from the meta-analysis
(see Fig. 1) are illustrated by arrows. Red and green colours depict
up-regulation and down-regulation, respectively
Fig. 5 Scatter plot on the influence of IUGR/ PE on transporter
expression. Each point represents one nutrient transporter, whose
X-axis is defined by its log (FC) expression value in the IUGR group,
and the Y-axis is presented by its log (FC) expression value in PE.
0.2 was defined as error threshold. The top 3 genes dominantly
influenced by the pathology of IUGR (SLC16A4, ABCA1, ABCG2) or
PE (SLC23A1, SLC7A11, SLC26A2), are marked with blue and yellow
squares, respectively. Red squares (SLC7A7, SLC7A8, SLC38A5) indicate
the transporters that receive comparable effects from IUGR and PE. The
points with cross mark depict the significantly regulated transporters
by a Kruskal-Wallis test. Abbreviations: log (FC): log 2 fold change
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aforementioned evidences, we considered the in-house
tissue samples applied in this study as adequate to reflect
patterns occurring in a wider target population.
We further analysed the impact of IUGR/PE on the
mRNA expression levels of the selected 46 transporters.
Overall, our quantitative RT-PCR measurements re-
vealed a differential expression pattern between control
and diseased placentae, including 8 significantly regu-
lated candidates, which might be critical for the fetal
malnutrition associated with IUGR/PE. Within this list,
SLC2A1 (GLUT1) has been repeatedly reported as sig-
nificantly reduced at the mRNA level by PE [39, 40].
The studies in animals, such as rat and sheep, have
shown that placental GLUT1 expression is significantly
decreased in IUGR [41, 42], which is consistent with our
findings. We also detected a mRNA down-regulation of
the thiamine transporter SLC19A3 and the putative pyri-
doxine transporter SLC22A15 in IUGR and PE. To our
knowledge, this is the first report demonstrating a re-
duction of placental SLC19A3 and SLC22A15 in IUGR
and PE. Currently, there is a lack of specific clinical data
on vitamin B1 or B6 deficiency during human preg-
nancy, except for B vitamin complex supplements. The
Fig. 6 Protein expression of the membrane transporters ABCA1, SLC7A7 and SLC38A5 in total tissue lysates. ABCA1 (a; 250 kD), SLC7A7 (b; 56 kD),
and SLC38A5 (c; 51 kD) protein expressions in total lysates were quantified from control and diseased placentas. Western blotting (upper panels)
was performed with 90 μg total lysates from term (n = 4), preterm (n = 5), IUGR (n = 6), PE + IUGR (n = 6), and PE (n = 5) (upper panels). After
overnight exposure, an immunoreactive signal was observed in all lanes at the expected size. Relative protein expression levels from western
blotting results were then calculated as the densitometric ratio of target versus β-actin (43 kD; lower panels). Data are expressed as median ±
range. Significance at p < 0.05 was assessed by a Kruskal-Wallis test, followed by Dunn’s multiple comparison
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in this study may raise our attention to serum thiamine
and pyridoxine alterations during pregnancy, which
could interrupt the structural and functional develop-
ment of cerebella and hippocampus, respectively. Infor-
mation on the sulfate transporter SLC26A2 in placenta
is very scarce. Only Simmons et al. recently reported an
abundant mRNA and CTB-specific expression of
SLC26A2 in human placenta [43]. In the present study,
we identified an up-regulation of SLC26A2 mRNA in
IUGR and a down-regulation in PE, based on our in
silico screening and the in house gene quantitation.
Those opposite but significant changes between IUGR
and PE may indicate a different role of SLC26A2 in
these two diseases which should be further investigated.
The cholesterol transporter ABCA1, as well as the
amino acid transporters SLC7A7 and SLC38A5 were
consecutively chosen as the main targets for further in-
vestigation, as they popped up both in the statistical ana-
lysis and the mathematical diagramming procedure. For
ABCA1, we have confirmed the previous finding of an
exclusively decreased ABCA1 expression in PE [21]. The
impaired ABCA1 function resulted in compromised
cholesterol and phospholipid efflux, hence a concomi-
tant accumulation of lipids was observed in PE placentas
[44]. The amino acid transporter SLC7A7 encodes the y
+LAT-1 protein, which is known to be located at the
MVM and BM [7]. It forms a heterodimer complex with
h4F2hc (encoded by SLC3A2), mediating the Na+-inde-
pendent cationic amino acids or large neutral L-amino
acids transport [45]. Our finding regarding the decrease
of SLC7A7 mRNA and protein in IUGR is in agreement
with a previous study using Slc7a7-/- mice [46], whichcaused fetal growth retardation by downregulating
insulin-like growth factor 1. In addition, we found an in-
creased SLC7A7 expression in diseases associated with
PE compared with gestational age-matched controls. As
lysine, arginine and ornithine are substrates for SLC7A7,
high SLC7A7 expression could cause reduced maternal
lysine, arginine and ornithine levels. During pregnancy
this may evoke similar symptoms as reported for lysinu-
ric protein intolerance, which has been associated with
serious gestational complications such as increased risk
of developing gestational anaemia and PE [47].
SLC38A5, also known as SNAT5 protein, belongs to the
Na+-coupled neutral amino acid transporter system N. It
mediates the cotransport of glycine, asparagine, alanine,
serine, glutamine and histidine with sodium [48]. Prior
to the current study, SLC38A5 has only been proven to
localize at the MVM and to participate in placental glu-
tamine homeostasis [49]. Our work reports for the first
time that SLC38A5 is differentially regulated (increased)
at mRNA level in the clinically highly relevant pregnancy
diseases IUGR and PE. The trend towards an elevated
expression as compared to the control groups was also
confirmed on protein level, but, supposedly due to the
lower sample size and higher variation in the Western
blotting experiments, the comparison between the groups
in the ANOVA was not statistically different. In compa-
rison, another sodium-coupled neural amino acid trans-
porter, SLC38A2, which is localized at both the MVM and
BM [50], was shown to be significantly decreased in IUGR
and PE in the mRNA screening (Fig. 4). The differentially
altered expression patterns of SLC38A5 and SLC38A2 in
IUGR and PE (up- versus down-regulation) might not
only result from their differing cellular localizations but
Fig. 7 Protein expression of the amino acid transporters SLC7A7 and SLC38A5 in enriched plasma membrane fractions. Representative Western
blots of SLC7A7 (a; 56 kD) and SLC38A5 (b; 51 kD) protein expression from isolated placental membrane fractions. Western blotting was performed
with 30 μg membrane proteins from term (n = 4), preterm (n = 5), IUGR (n = 6), PE + IUGR (n = 6), and PE (n = 5) (Left panels). Both β-actin (43 kD) and
Na+/K+ ATPase (112 kD) were used as loading controls. Relative protein expression levels from western blotting results were then calculated as the
densitometric ratio of targeted transporter versus β-actin (43 kD; upper right panel) and Na+/K+ ATPase (112 kD; lower right panel). Data are expressed
as median ± range. Based on Kruskal-Wallis test followed by Dunn’s multiple comparison, *, ** denote p < 0.05 and < 0.01, respectively
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as a member of system A, is a pH sensitive uniporter.
However, SLC38A5 exhibits marked inhibition at low
extracellular pH, because it mediates also the coupled
countertransport of H+ with the substrate (e.g. glutamine)
[51]. Therefore, the uptake or efflux of glutamine via
SLC38A5 may strongly depend on the cellular metabolic
status, which could be modified in gestational disorders
such as IUGR and PE.
Conclusions
The current study reports a novel analytic strategy includ-
ing bioinformatic analysis of publicly available microarray
datasets, followed by molecular biological and biochemical
quantification of mRNA and protein expression inbiological tissue samples combined with mathematical
diagramming. This approach was successfully applied,
firstly to provide an overview on placental membrane
transporters providing the fetus with optimal nutrients
and microelements for adequate fetal growth, and sec-
ondly, to explore the significance of altered membrane
transporter expressions in the clinically important preg-
nancy diseases IUGR and PE. A systematic change in nu-
trient transporter expression was detected, and 8
membrane transporters were found to be significantly reg-
ulated in IUGR/PE. Particularly, the amino acid trans-
porters SLC7A7 and SLC38A5, were influenced by both
IUGR and PE. In the present study, we demonstrated for
the first time an enhanced mRNA expression of SLC38A5
in IUGR and PE placentae and the same trend on protein
Huang et al. BMC Genomics  (2018) 19:173 Page 13 of 17level. These findings are the basis for future investigations
which should examine function of the selected trans-
porters at different regions in placenta and elucidate the
precise mechanisms regulating the observed changes in
IUGR and/or PE.
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